Drugs / hBMMSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07177677 | Sep 2025 → Dec 2026 expected | autism spectrum disorder | Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hBMMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07177677 ↗ |
| Known as | human Bone Marrow Mesenchymal Stem Cell | “human Bone Marrow Mesenchymal Stem Cell (hBMMSC)” NCT07177677 ↗ |
| Modality | Cell therapy | “human bone marrow-derived mesenchymal stem cells (hBMMSCs)” NCT07177677 ↗ |
| Route | Intravenous | “intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs)” NCT07177677 ↗ |